 [
    {
        "id": 5898,
        "drug_name": "MenQuadfi",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Meningococcal meningitis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-04-24",
        "link": "https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2020\/2020-04-24-07-00-00",
        "note": "FDA approval announced April 24, 2020.",
        "company_entity_id": 389,
        "company_ticker": "SNY",
        "company_name": "Sanofi",
        "company_price": "48.4600",
        "company_change": 0.11,
        "company_percent_change": 0.23,
        "company_optionable": 1,
        "company_number_of_shares": 2529599938,
        "price_change_sparkline": [
            [
                49.9,
                1706677200
            ],
            [
                48.41,
                1706763600
            ],
            [
                47.23,
                1706850000
            ],
            [
                46.95,
                1707109200
            ],
            [
                47.06,
                1707195600
            ],
            [
                46.92,
                1707282000
            ],
            [
                46.56,
                1707368400
            ],
            [
                46.5,
                1707454800
            ],
            [
                46.34,
                1707714000
            ],
            [
                45.75,
                1707800400
            ],
            [
                45.8,
                1707886800
            ],
            [
                46.39,
                1707973200
            ],
            [
                46.18,
                1708059600
            ],
            [
                46.85,
                1708405200
            ],
            [
                47.92,
                1708491600
            ],
            [
                47.8,
                1708578000
            ],
            [
                48.77,
                1708664400
            ],
            [
                48.2,
                1708923600
            ],
            [
                48.21,
                1709010000
            ],
            [
                48,
                1709096400
            ],
            [
                47.85,
                1709182800
            ],
            [
                47.29,
                1709269200
            ],
            [
                47.15,
                1709528400
            ],
            [
                47.5,
                1709614800
            ],
            [
                47.68,
                1709701200
            ],
            [
                48.06,
                1709787600
            ],
            [
                48.25,
                1709874000
            ],
            [
                48.35,
                1710129600
            ],
            [
                48.46,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2735,
        "drug_name": "Opicapone",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Parkinson's disease",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-04-27",
        "link": "https:\/\/www.benzinga.com\/pressreleases\/20\/04\/n15882847\/neurocrine-biosciences-announces-fda-approval-of-once-daily-ongentys-opicapone-as-an-add-on-treatm",
        "note": "FDA Approval announced April 27, 2020.",
        "company_entity_id": 205,
        "company_ticker": "NBIX",
        "company_name": "Neurocrine Biosciences Inc.",
        "company_price": "137.7400",
        "company_change": -0.87,
        "company_percent_change": -0.63,
        "company_optionable": 1,
        "company_number_of_shares": 99507490,
        "price_change_sparkline": [
            [
                139.77,
                1706677200
            ],
            [
                142.45,
                1706763600
            ],
            [
                141.74,
                1706850000
            ],
            [
                141.66,
                1707109200
            ],
            [
                142.96,
                1707195600
            ],
            [
                136.29,
                1707282000
            ],
            [
                134.42,
                1707368400
            ],
            [
                132.3,
                1707454800
            ],
            [
                130.43,
                1707714000
            ],
            [
                133.84,
                1707800400
            ],
            [
                131.77,
                1707886800
            ],
            [
                134,
                1707973200
            ],
            [
                132.31,
                1708059600
            ],
            [
                132.65,
                1708405200
            ],
            [
                130.65,
                1708491600
            ],
            [
                133.37,
                1708578000
            ],
            [
                134.18,
                1708664400
            ],
            [
                135.58,
                1708923600
            ],
            [
                136.03,
                1709010000
            ],
            [
                134.66,
                1709096400
            ],
            [
                130.4,
                1709182800
            ],
            [
                131.3,
                1709269200
            ],
            [
                133.12,
                1709528400
            ],
            [
                133.67,
                1709614800
            ],
            [
                132.25,
                1709701200
            ],
            [
                135.33,
                1709787600
            ],
            [
                139.22,
                1709874000
            ],
            [
                138.61,
                1710129600
            ],
            [
                137.74,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2667,
        "drug_name": "ZEJULA (Niraparib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Ovarian cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-04-29",
        "link": "https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/fda-approves-parp-inhibitor-in-first-line-monotherapy-maintenance-treatment-for-women-with-platinum-responsive-advanced-ovarian-cancer-regardless-of-biomarker-status\/",
        "note": "FDA Approval announced April 29, 2020.",
        "company_entity_id": 379,
        "company_ticker": "GSK",
        "company_name": "GSK plc American Depositary Shares (Each representing two)",
        "company_price": "43.2700",
        "company_change": 0.35,
        "company_percent_change": 0.82,
        "company_optionable": 1,
        "company_number_of_shares": 2058516719,
        "price_change_sparkline": [
            [
                39.0637603938206,
                1706677200
            ],
            [
                40.2424083367376,
                1706763600
            ],
            [
                40.3315497777986,
                1706850000
            ],
            [
                41.1734411655964,
                1707109200
            ],
            [
                41.3517240477183,
                1707195600
            ],
            [
                41.6191483709012,
                1707282000
            ],
            [
                41.4210562796546,
                1707368400
            ],
            [
                41.5101977207156,
                1707454800
            ],
            [
                40.67821093748,
                1707714000
            ],
            [
                40.9951582834745,
                1707800400
            ],
            [
                41.40124707053,
                1707886800
            ],
            [
                41.371533256843,
                1707973200
            ],
            [
                41.5399115344025,
                1708059600
            ],
            [
                41.6191483709012,
                1708405200
            ],
            [
                41.5399115344025,
                1708491600
            ],
            [
                42.16,
                1708578000
            ],
            [
                42.22,
                1708664400
            ],
            [
                42.34,
                1708923600
            ],
            [
                42.38,
                1709010000
            ],
            [
                42.34,
                1709096400
            ],
            [
                41.9,
                1709182800
            ],
            [
                42.03,
                1709269200
            ],
            [
                42.44,
                1709528400
            ],
            [
                42.6,
                1709614800
            ],
            [
                42.62,
                1709701200
            ],
            [
                43.58,
                1709787600
            ],
            [
                43.14,
                1709874000
            ],
            [
                42.92,
                1710129600
            ],
            [
                43.27,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2667,
        "drug_name": "ZEJULA (Niraparib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Ovarian cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-04-29",
        "link": "https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/fda-approves-parp-inhibitor-in-first-line-monotherapy-maintenance-treatment-for-women-with-platinum-responsive-advanced-ovarian-cancer-regardless-of-biomarker-status\/",
        "note": "FDA Approval announced April 29, 2020.",
        "company_entity_id": 484,
        "company_ticker": "ZLAB",
        "company_name": "Zai Lab Limited",
        "company_price": "19.5400",
        "company_change": -0.47,
        "company_percent_change": -2.35,
        "company_optionable": 1,
        "company_number_of_shares": 99208743,
        "price_change_sparkline": [
            [
                21.57,
                1706677200
            ],
            [
                22.51,
                1706763600
            ],
            [
                22.5,
                1706850000
            ],
            [
                22.12,
                1707109200
            ],
            [
                21.61,
                1707195600
            ],
            [
                19.66,
                1707282000
            ],
            [
                19.605,
                1707368400
            ],
            [
                18.68,
                1707454800
            ],
            [
                18.21,
                1707714000
            ],
            [
                17.73,
                1707800400
            ],
            [
                19.39,
                1707886800
            ],
            [
                19.89,
                1707973200
            ],
            [
                20.64,
                1708059600
            ],
            [
                19.24,
                1708405200
            ],
            [
                19.91,
                1708491600
            ],
            [
                20.08,
                1708578000
            ],
            [
                19.94,
                1708664400
            ],
            [
                20.99,
                1708923600
            ],
            [
                22.49,
                1709010000
            ],
            [
                20.8,
                1709096400
            ],
            [
                20.98,
                1709182800
            ],
            [
                21.1,
                1709269200
            ],
            [
                20.42,
                1709528400
            ],
            [
                18.91,
                1709614800
            ],
            [
                19.8,
                1709701200
            ],
            [
                19.16,
                1709787600
            ],
            [
                18.91,
                1709874000
            ],
            [
                20.01,
                1710129600
            ],
            [
                19.54,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2908,
        "drug_name": "OTEZLA",
        "clinical_trial_id": "NCT03059953",
        "has_trial_insight_page": 0,
        "indication": "Scalp Psoriasis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-04-30",
        "link": "http:\/\/investors.amgen.com\/news-releases\/news-release-details\/amgen-reports-first-quarter-2020-financial-results",
        "note": "FDA approval announced April 2020.",
        "company_entity_id": 372,
        "company_ticker": "AMGN",
        "company_name": "Amgen Inc.",
        "company_price": "276.5400",
        "company_change": 1.18,
        "company_percent_change": 0.43,
        "company_optionable": 1,
        "company_number_of_shares": 535918901,
        "price_change_sparkline": [
            [
                311.832823699025,
                1706677200
            ],
            [
                322.053272003295,
                1706763600
            ],
            [
                320.693853151174,
                1706850000
            ],
            [
                319.483275779212,
                1707109200
            ],
            [
                313.62884422628,
                1707195600
            ],
            [
                293.584858231498,
                1707282000
            ],
            [
                292.572736166415,
                1707368400
            ],
            [
                288.871544693121,
                1707454800
            ],
            [
                292.155980021969,
                1707714000
            ],
            [
                288.236487711108,
                1707800400
            ],
            [
                287.829654332006,
                1707886800
            ],
            [
                289.07,
                1707973200
            ],
            [
                283.7,
                1708059600
            ],
            [
                283.51,
                1708405200
            ],
            [
                283.46,
                1708491600
            ],
            [
                285.18,
                1708578000
            ],
            [
                289.18,
                1708664400
            ],
            [
                286.37,
                1708923600
            ],
            [
                278.49,
                1709010000
            ],
            [
                277.46,
                1709096400
            ],
            [
                273.83,
                1709182800
            ],
            [
                280.33,
                1709269200
            ],
            [
                279.39,
                1709528400
            ],
            [
                276.65,
                1709614800
            ],
            [
                276.59,
                1709701200
            ],
            [
                272.86,
                1709787600
            ],
            [
                273.75,
                1709874000
            ],
            [
                275.36,
                1710129600
            ],
            [
                276.54,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5408,
        "drug_name": "DARZALEX (Daratumumab) using ENHANZE",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Multiple myeloma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-05-01",
        "link": "http:\/\/johnsonandjohnson.gcs-web.com\/static-files\/65c8f0c9-6c40-4143-95e5-f65bb03bae9f",
        "note": "FDA Approval announced May 1, 2020.",
        "company_entity_id": 380,
        "company_ticker": "JNJ",
        "company_name": "Johnson & Johnson",
        "company_price": "162.7400",
        "company_change": 1.51,
        "company_percent_change": 0.94,
        "company_optionable": 1,
        "company_number_of_shares": 2408767228,
        "price_change_sparkline": [
            [
                157.701248890579,
                1706677200
            ],
            [
                157.165322682896,
                1706763600
            ],
            [
                155.428524787625,
                1706850000
            ],
            [
                154.6246354761,
                1707109200
            ],
            [
                156.867585900849,
                1707195600
            ],
            [
                156.788189425637,
                1707282000
            ],
            [
                155.220109040193,
                1707368400
            ],
            [
                155.577393178648,
                1707454800
            ],
            [
                156.659170153417,
                1707714000
            ],
            [
                155.289580956004,
                1707800400
            ],
            [
                154.565088119691,
                1707886800
            ],
            [
                156.728642069228,
                1707973200
            ],
            [
                156.55,
                1708059600
            ],
            [
                157.86,
                1708405200
            ],
            [
                158.68,
                1708491600
            ],
            [
                160.45,
                1708578000
            ],
            [
                161.84,
                1708664400
            ],
            [
                160.79,
                1708923600
            ],
            [
                160.98,
                1709010000
            ],
            [
                161.55,
                1709096400
            ],
            [
                161.38,
                1709182800
            ],
            [
                162.12,
                1709269200
            ],
            [
                159.84,
                1709528400
            ],
            [
                159.97,
                1709614800
            ],
            [
                159.34,
                1709701200
            ],
            [
                158.87,
                1709787600
            ],
            [
                159.52,
                1709874000
            ],
            [
                161.23,
                1710129600
            ],
            [
                162.74,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5408,
        "drug_name": "DARZALEX (Daratumumab) using ENHANZE",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Multiple myeloma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-05-01",
        "link": "http:\/\/johnsonandjohnson.gcs-web.com\/static-files\/65c8f0c9-6c40-4143-95e5-f65bb03bae9f",
        "note": "FDA Approval announced May 1, 2020.",
        "company_entity_id": 156,
        "company_ticker": "HALO",
        "company_name": "Halozyme Therapeutics Inc.",
        "company_price": "41.9500",
        "company_change": 0.75,
        "company_percent_change": 1.8199999999999998,
        "company_optionable": 1,
        "company_number_of_shares": 126824800,
        "price_change_sparkline": [
            [
                33.85,
                1706677200
            ],
            [
                34.26,
                1706763600
            ],
            [
                33.68,
                1706850000
            ],
            [
                33.68,
                1707109200
            ],
            [
                35.02,
                1707195600
            ],
            [
                35.31,
                1707282000
            ],
            [
                35.24,
                1707368400
            ],
            [
                35.49,
                1707454800
            ],
            [
                35.69,
                1707714000
            ],
            [
                34.64,
                1707800400
            ],
            [
                35.06,
                1707886800
            ],
            [
                35.91,
                1707973200
            ],
            [
                36.1,
                1708059600
            ],
            [
                36,
                1708405200
            ],
            [
                38.36,
                1708491600
            ],
            [
                39.72,
                1708578000
            ],
            [
                40.56,
                1708664400
            ],
            [
                39.67,
                1708923600
            ],
            [
                39.84,
                1709010000
            ],
            [
                39.69,
                1709096400
            ],
            [
                39.81,
                1709182800
            ],
            [
                41.11,
                1709269200
            ],
            [
                40.93,
                1709528400
            ],
            [
                41.41,
                1709614800
            ],
            [
                41.69,
                1709701200
            ],
            [
                41.71,
                1709787600
            ],
            [
                41.73,
                1709874000
            ],
            [
                41.2,
                1710129600
            ],
            [
                41.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5408,
        "drug_name": "DARZALEX (Daratumumab) using ENHANZE",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Multiple myeloma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-05-01",
        "link": "http:\/\/johnsonandjohnson.gcs-web.com\/static-files\/65c8f0c9-6c40-4143-95e5-f65bb03bae9f",
        "note": "FDA Approval announced May 1, 2020.",
        "company_entity_id": 684,
        "company_ticker": "GMAB",
        "company_name": "Genmab A\/S",
        "company_price": "31.4300",
        "company_change": -0.25,
        "company_percent_change": -0.79,
        "company_optionable": 1,
        "company_number_of_shares": 660745350,
        "price_change_sparkline": [
            [
                27.61,
                1706677200
            ],
            [
                28.17,
                1706763600
            ],
            [
                27.8,
                1706850000
            ],
            [
                27.57,
                1707109200
            ],
            [
                28.15,
                1707195600
            ],
            [
                27.97,
                1707282000
            ],
            [
                27.79,
                1707368400
            ],
            [
                27.84,
                1707454800
            ],
            [
                27.49,
                1707714000
            ],
            [
                26.43,
                1707800400
            ],
            [
                27.59,
                1707886800
            ],
            [
                28.23,
                1707973200
            ],
            [
                28.71,
                1708059600
            ],
            [
                28.95,
                1708405200
            ],
            [
                28.95,
                1708491600
            ],
            [
                29.11,
                1708578000
            ],
            [
                29.16,
                1708664400
            ],
            [
                29.4,
                1708923600
            ],
            [
                29.05,
                1709010000
            ],
            [
                27.67,
                1709096400
            ],
            [
                27.77,
                1709182800
            ],
            [
                29.29,
                1709269200
            ],
            [
                28.51,
                1709528400
            ],
            [
                28.75,
                1709614800
            ],
            [
                28.86,
                1709701200
            ],
            [
                29.41,
                1709787600
            ],
            [
                30.3,
                1709874000
            ],
            [
                31.68,
                1710129600
            ],
            [
                31.43,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2569,
        "drug_name": "FARXIGA (Dapagliflozin)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Heart failure",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-05-05",
        "link": "https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2020\/farxiga-approved-in-the-us-for-the-treatment-of-heart-failure-in-patients-with-heart-failure-with-reduced-ejection-fraction.html",
        "note": "FDA Approval announced May 5, 2020.",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4450,
        "drug_name": "TABRECTA (capmatinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Non-small cell lung cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-05-06",
        "link": "https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/00c96988-d987-4a36-9538-424ddaff26fd",
        "note": "FDA Approval announced May 6, 2020.",
        "company_entity_id": 386,
        "company_ticker": "NVS",
        "company_name": "Novartis AG",
        "company_price": "99.7700",
        "company_change": -1.6,
        "company_percent_change": -1.58,
        "company_optionable": 1,
        "company_number_of_shares": 2044033986,
        "price_change_sparkline": [
            [
                99.701426650332,
                1706677200
            ],
            [
                101.493681927897,
                1706763600
            ],
            [
                99.9423211768864,
                1706850000
            ],
            [
                99.701426650332,
                1707109200
            ],
            [
                99.9615927390107,
                1707195600
            ],
            [
                99.6917908692698,
                1707282000
            ],
            [
                97.6682768462129,
                1707368400
            ],
            [
                97.3502960711611,
                1707454800
            ],
            [
                96.8685070180523,
                1707714000
            ],
            [
                95.4520472019125,
                1707800400
            ],
            [
                95.4424114208503,
                1707886800
            ],
            [
                96.0012867224565,
                1707973200
            ],
            [
                96.5408904619384,
                1708059600
            ],
            [
                98.9787430706688,
                1708405200
            ],
            [
                98.824570573674,
                1708491600
            ],
            [
                99.0558293191662,
                1708578000
            ],
            [
                100.115765236006,
                1708664400
            ],
            [
                99.4894394669641,
                1708923600
            ],
            [
                99.3930816563424,
                1709010000
            ],
            [
                98.49695401756,
                1709096400
            ],
            [
                97.2924813847881,
                1709182800
            ],
            [
                98.3427815205652,
                1709269200
            ],
            [
                98.2560594910056,
                1709528400
            ],
            [
                98.3813246448139,
                1709614800
            ],
            [
                98.9016568221714,
                1709701200
            ],
            [
                99.93,
                1709787600
            ],
            [
                100.71,
                1709874000
            ],
            [
                101.37,
                1710129600
            ],
            [
                99.77,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4450,
        "drug_name": "TABRECTA (capmatinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Non-small cell lung cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-05-06",
        "link": "https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/00c96988-d987-4a36-9538-424ddaff26fd",
        "note": "FDA Approval announced May 6, 2020.",
        "company_entity_id": 167,
        "company_ticker": "INCY",
        "company_name": "Incyte Corporation",
        "company_price": "59.3300",
        "company_change": -1.46,
        "company_percent_change": -2.4,
        "company_optionable": 1,
        "company_number_of_shares": 224526128,
        "price_change_sparkline": [
            [
                58.77,
                1706677200
            ],
            [
                59.16,
                1706763600
            ],
            [
                58.35,
                1706850000
            ],
            [
                58.06,
                1707109200
            ],
            [
                59.63,
                1707195600
            ],
            [
                57.34,
                1707282000
            ],
            [
                57.36,
                1707368400
            ],
            [
                57.66,
                1707454800
            ],
            [
                57.84,
                1707714000
            ],
            [
                59.34,
                1707800400
            ],
            [
                57.89,
                1707886800
            ],
            [
                58.97,
                1707973200
            ],
            [
                57.96,
                1708059600
            ],
            [
                58.82,
                1708405200
            ],
            [
                60.33,
                1708491600
            ],
            [
                60.91,
                1708578000
            ],
            [
                60.59,
                1708664400
            ],
            [
                60.53,
                1708923600
            ],
            [
                61,
                1709010000
            ],
            [
                59.98,
                1709096400
            ],
            [
                58.36,
                1709182800
            ],
            [
                59.05,
                1709269200
            ],
            [
                59.72,
                1709528400
            ],
            [
                58.9,
                1709614800
            ],
            [
                59.26,
                1709701200
            ],
            [
                59.03,
                1709787600
            ],
            [
                60.02,
                1709874000
            ],
            [
                60.79,
                1710129600
            ],
            [
                59.33,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6354,
        "drug_name": "RETEVMO (Selpercatinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Non-small cell lung cancer, medullary thyroid cancer and thyroid cancer. ",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-05-08",
        "link": "https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lilly-receives-us-fda-approval-retevmotm-selpercatinib-first",
        "note": "FDA Approval announced May 8, 2020.",
        "company_entity_id": 382,
        "company_ticker": "LLY",
        "company_name": "Eli Lilly and Company",
        "company_price": "754.9500",
        "company_change": 20.58,
        "company_percent_change": 2.8,
        "company_optionable": 1,
        "company_number_of_shares": 950164452,
        "price_change_sparkline": [
            [
                644.503643637706,
                1706677200
            ],
            [
                659.298247188938,
                1706763600
            ],
            [
                666.505874560051,
                1706850000
            ],
            [
                704.989812947364,
                1707109200
            ],
            [
                703.821817930162,
                1707195600
            ],
            [
                724.13694493877,
                1707282000
            ],
            [
                734.41929423551,
                1707368400
            ],
            [
                738.891617036422,
                1707454800
            ],
            [
                735.996586651903,
                1707714000
            ],
            [
                741.696801650387,
                1707800400
            ],
            [
                757.31,
                1707886800
            ],
            [
                757.78,
                1707973200
            ],
            [
                782.06,
                1708059600
            ],
            [
                755.66,
                1708405200
            ],
            [
                745.91,
                1708491600
            ],
            [
                769.64,
                1708578000
            ],
            [
                769.54,
                1708664400
            ],
            [
                771.92,
                1708923600
            ],
            [
                765,
                1709010000
            ],
            [
                757.64,
                1709096400
            ],
            [
                753.68,
                1709182800
            ],
            [
                782.12,
                1709269200
            ],
            [
                792.28,
                1709528400
            ],
            [
                777.59,
                1709614800
            ],
            [
                779.77,
                1709701200
            ],
            [
                780.16,
                1709787600
            ],
            [
                762.14,
                1709874000
            ],
            [
                734.37,
                1710129600
            ],
            [
                754.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4937,
        "drug_name": "LYNPARZA (olaparib) + AVASTIN (bevacizumab) - PAOLA-1",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "First-line ovarian cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-05-08",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200508005523\/en\/",
        "note": "FDA Approval announced May 8, 2020.",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4937,
        "drug_name": "LYNPARZA (olaparib) + AVASTIN (bevacizumab) - PAOLA-1",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "First-line ovarian cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-05-08",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200508005523\/en\/",
        "note": "FDA Approval announced May 8, 2020.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5806,
        "drug_name": "POMALYST (pomalidomide)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Kaposi\u2019s sarcoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-05-15",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200515005277\/en\/",
        "note": "FDA Approval announced May 15, 2020.",
        "company_entity_id": 376,
        "company_ticker": "BMY",
        "company_name": "Bristol-Myers Squibb Company",
        "company_price": "54.4000",
        "company_change": 0.04,
        "company_percent_change": 0.07,
        "company_optionable": 1,
        "company_number_of_shares": 2022193411,
        "price_change_sparkline": [
            [
                48.87,
                1706677200
            ],
            [
                48.67,
                1706763600
            ],
            [
                48.71,
                1706850000
            ],
            [
                47.98,
                1707109200
            ],
            [
                49.26,
                1707195600
            ],
            [
                48.64,
                1707282000
            ],
            [
                48.71,
                1707368400
            ],
            [
                49.81,
                1707454800
            ],
            [
                49.75,
                1707714000
            ],
            [
                48.71,
                1707800400
            ],
            [
                48.89,
                1707886800
            ],
            [
                49.44,
                1707973200
            ],
            [
                49.86,
                1708059600
            ],
            [
                49.86,
                1708405200
            ],
            [
                50.91,
                1708491600
            ],
            [
                51.33,
                1708578000
            ],
            [
                51.66,
                1708664400
            ],
            [
                50.52,
                1708923600
            ],
            [
                50.51,
                1709010000
            ],
            [
                50.92,
                1709096400
            ],
            [
                50.75,
                1709182800
            ],
            [
                50.89,
                1709269200
            ],
            [
                50.92,
                1709528400
            ],
            [
                51.82,
                1709614800
            ],
            [
                53.38,
                1709701200
            ],
            [
                53.28,
                1709787600
            ],
            [
                53.79,
                1709874000
            ],
            [
                54.36,
                1710129600
            ],
            [
                54.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2445,
        "drug_name": "RUBRACA (rucaparib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Castrate-resistant prostate cancer (mCRPC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-05-15",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200515005527\/en\/",
        "note": "FDA Approval announced May 15, 2020.",
        "company_entity_id": 93,
        "company_ticker": "CLVS",
        "company_name": "Clovis Oncology Inc.",
        "company_price": "0.0812",
        "company_change": 0,
        "company_percent_change": 0,
        "company_optionable": 0,
        "company_number_of_shares": 144955263,
        "statuses": []
    },
    {
        "id": 2216,
        "drug_name": "QINLOCK (ripretinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Gastrointestinal Stromal Tumors (GIST) - fourth-line",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-05-15",
        "link": "https:\/\/investors.deciphera.com\/news-releases\/news-release-details\/deciphera-pharmaceuticals-announces-us-food-and-drug",
        "note": "FDA Approval announced May 15, 2020.",
        "company_entity_id": 472,
        "company_ticker": "DCPH",
        "company_name": "Deciphera Pharmaceuticals Inc.",
        "company_price": "16.0900",
        "company_change": -0.44999999999999996,
        "company_percent_change": -2.7199999999999998,
        "company_optionable": 1,
        "company_number_of_shares": 80800062,
        "price_change_sparkline": [
            [
                14.32,
                1706677200
            ],
            [
                14.76,
                1706763600
            ],
            [
                14.48,
                1706850000
            ],
            [
                14.76,
                1707109200
            ],
            [
                14.83,
                1707195600
            ],
            [
                14.02,
                1707282000
            ],
            [
                14.17,
                1707368400
            ],
            [
                15.73,
                1707454800
            ],
            [
                15.58,
                1707714000
            ],
            [
                14.5,
                1707800400
            ],
            [
                15.28,
                1707886800
            ],
            [
                15.92,
                1707973200
            ],
            [
                15.67,
                1708059600
            ],
            [
                15.55,
                1708405200
            ],
            [
                15.4,
                1708491600
            ],
            [
                15.75,
                1708578000
            ],
            [
                16.06,
                1708664400
            ],
            [
                16.44,
                1708923600
            ],
            [
                16.91,
                1709010000
            ],
            [
                16.81,
                1709096400
            ],
            [
                16.69,
                1709182800
            ],
            [
                17.36,
                1709269200
            ],
            [
                16.61,
                1709528400
            ],
            [
                16.8,
                1709614800
            ],
            [
                16.93,
                1709701200
            ],
            [
                16.93,
                1709787600
            ],
            [
                16.94,
                1709874000
            ],
            [
                16.54,
                1710129600
            ],
            [
                16.09,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2949,
        "drug_name": "OPDIVO (nivolumab) + YERVOY (ipilimumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "First-line Non-small cell lung cancer (NSCLC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-05-15",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200515005557\/en\/",
        "note": "FDA Approval announced May 15, 2020.",
        "company_entity_id": 376,
        "company_ticker": "BMY",
        "company_name": "Bristol-Myers Squibb Company",
        "company_price": "54.4000",
        "company_change": 0.04,
        "company_percent_change": 0.07,
        "company_optionable": 1,
        "company_number_of_shares": 2022193411,
        "price_change_sparkline": [
            [
                48.87,
                1706677200
            ],
            [
                48.67,
                1706763600
            ],
            [
                48.71,
                1706850000
            ],
            [
                47.98,
                1707109200
            ],
            [
                49.26,
                1707195600
            ],
            [
                48.64,
                1707282000
            ],
            [
                48.71,
                1707368400
            ],
            [
                49.81,
                1707454800
            ],
            [
                49.75,
                1707714000
            ],
            [
                48.71,
                1707800400
            ],
            [
                48.89,
                1707886800
            ],
            [
                49.44,
                1707973200
            ],
            [
                49.86,
                1708059600
            ],
            [
                49.86,
                1708405200
            ],
            [
                50.91,
                1708491600
            ],
            [
                51.33,
                1708578000
            ],
            [
                51.66,
                1708664400
            ],
            [
                50.52,
                1708923600
            ],
            [
                50.51,
                1709010000
            ],
            [
                50.92,
                1709096400
            ],
            [
                50.75,
                1709182800
            ],
            [
                50.89,
                1709269200
            ],
            [
                50.92,
                1709528400
            ],
            [
                51.82,
                1709614800
            ],
            [
                53.38,
                1709701200
            ],
            [
                53.28,
                1709787600
            ],
            [
                53.79,
                1709874000
            ],
            [
                54.36,
                1710129600
            ],
            [
                54.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6069,
        "drug_name": "TECENTRIQ (atezolizumab) - IMpower110",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Non-small cell lung cancer (NSCLC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-05-18",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200518005690\/en\/",
        "note": "FDA Approval announced May 18, 2020.",
        "company_entity_id": 536,
        "company_ticker": "RHHBY",
        "company_name": "Roche Holding AG ADR",
        "company_price": "35.1500",
        "company_change": 0.54,
        "company_percent_change": 1.56,
        "company_optionable": 0,
        "company_number_of_shares": 6389213336,
        "price_change_sparkline": [
            [
                35.14,
                1706677200
            ],
            [
                34.32,
                1706763600
            ],
            [
                33.95,
                1706850000
            ],
            [
                33.16,
                1707109200
            ],
            [
                33.27,
                1707195600
            ],
            [
                32.55,
                1707282000
            ],
            [
                32.1,
                1707368400
            ],
            [
                32.31,
                1707454800
            ],
            [
                32.6,
                1707714000
            ],
            [
                32.13,
                1707800400
            ],
            [
                32.02,
                1707886800
            ],
            [
                32.1,
                1707973200
            ],
            [
                32.28,
                1708059600
            ],
            [
                32.74,
                1708405200
            ],
            [
                32.91,
                1708491600
            ],
            [
                32.49,
                1708578000
            ],
            [
                32.96,
                1708664400
            ],
            [
                32.52,
                1708923600
            ],
            [
                33.03,
                1709010000
            ],
            [
                32.93,
                1709096400
            ],
            [
                32.73,
                1709182800
            ],
            [
                33.08,
                1709269200
            ],
            [
                32.88,
                1709528400
            ],
            [
                33.15,
                1709614800
            ],
            [
                33.47,
                1709701200
            ],
            [
                33.77,
                1709787600
            ],
            [
                33.9,
                1709874000
            ],
            [
                34.61,
                1710129600
            ],
            [
                35.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4831,
        "drug_name": "LYNPARZA (olaparib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Castration-Resistant Prostate Cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-05-19",
        "link": "https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2020\/lynparza-approved-in-the-us-for-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer.html",
        "note": "FDA Approval announced May 19, 2020.",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4831,
        "drug_name": "LYNPARZA (olaparib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Castration-Resistant Prostate Cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-05-19",
        "link": "https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2020\/lynparza-approved-in-the-us-for-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer.html",
        "note": "FDA Approval announced May 19, 2020.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5330,
        "drug_name": "APL-130277",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Parkinson\u2019s Disease with motor fluctuations",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-05-21",
        "link": "https:\/\/www.globenewswire.com\/news-release\/2020\/05\/21\/2037338\/0\/en\/Aquestive-Therapeutics-Advances-Royalty-Monetization-Plan-as-Sunovion-Pharmaceuticals-Apomorphine-Sublingual-Film-Therapy-Receives-FDA-Approval.html",
        "note": "FDA approval announced May 21, 2020.",
        "company_entity_id": 582,
        "company_ticker": "AQST",
        "company_name": "Aquestive Therapeutics Inc.",
        "company_price": "5.1000",
        "company_change": 0.16,
        "company_percent_change": 3.24,
        "company_optionable": 1,
        "company_number_of_shares": 73301201,
        "price_change_sparkline": [
            [
                2.39,
                1706677200
            ],
            [
                2.67,
                1706763600
            ],
            [
                2.63,
                1706850000
            ],
            [
                2.7,
                1707109200
            ],
            [
                2.79,
                1707195600
            ],
            [
                2.64,
                1707282000
            ],
            [
                2.68,
                1707368400
            ],
            [
                2.75,
                1707454800
            ],
            [
                2.77,
                1707714000
            ],
            [
                2.65,
                1707800400
            ],
            [
                2.68,
                1707886800
            ],
            [
                2.72,
                1707973200
            ],
            [
                2.695,
                1708059600
            ],
            [
                2.65,
                1708405200
            ],
            [
                2.51,
                1708491600
            ],
            [
                2.63,
                1708578000
            ],
            [
                2.57,
                1708664400
            ],
            [
                2.85,
                1708923600
            ],
            [
                3.2,
                1709010000
            ],
            [
                3.65,
                1709096400
            ],
            [
                3.67,
                1709182800
            ],
            [
                4.24,
                1709269200
            ],
            [
                4.18,
                1709528400
            ],
            [
                4.19,
                1709614800
            ],
            [
                5.03,
                1709701200
            ],
            [
                5.68,
                1709787600
            ],
            [
                4.88,
                1709874000
            ],
            [
                4.94,
                1710129600
            ],
            [
                5.1,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6618,
        "drug_name": "ALUNBRIG (brigatinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "ALK+ Metastatic Non-Small Cell Lung Cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-05-22",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200522005448\/en\/",
        "note": "FDA Approval announced May 22, 2020.",
        "company_entity_id": 751,
        "company_ticker": "TAK",
        "company_name": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1\/2 of a share of)",
        "company_price": "14.3700",
        "company_change": -0.19999999999999996,
        "company_percent_change": -1.37,
        "company_optionable": 1,
        "company_number_of_shares": 3137776702,
        "price_change_sparkline": [
            [
                14.6,
                1706677200
            ],
            [
                14.38,
                1706763600
            ],
            [
                14.28,
                1706850000
            ],
            [
                13.92,
                1707109200
            ],
            [
                14.16,
                1707195600
            ],
            [
                14.18,
                1707282000
            ],
            [
                14,
                1707368400
            ],
            [
                14.24,
                1707454800
            ],
            [
                14.31,
                1707714000
            ],
            [
                14.34,
                1707800400
            ],
            [
                14.54,
                1707886800
            ],
            [
                14.42,
                1707973200
            ],
            [
                14.62,
                1708059600
            ],
            [
                14.82,
                1708405200
            ],
            [
                14.74,
                1708491600
            ],
            [
                14.64,
                1708578000
            ],
            [
                14.62,
                1708664400
            ],
            [
                14.81,
                1708923600
            ],
            [
                14.84,
                1709010000
            ],
            [
                14.65,
                1709096400
            ],
            [
                14.59,
                1709182800
            ],
            [
                14.56,
                1709269200
            ],
            [
                14.48,
                1709528400
            ],
            [
                14.4,
                1709614800
            ],
            [
                14.69,
                1709701200
            ],
            [
                14.86,
                1709787600
            ],
            [
                14.77,
                1709874000
            ],
            [
                14.57,
                1710129600
            ],
            [
                14.37,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 1912,
        "drug_name": "PHEXXI (Amphora)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "contraceptive vaginal gel",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-05-22",
        "link": "https:\/\/evofem.investorroom.com\/2020-05-22-U-S-FDA-Approves-Evofem-Biosciences-Phexxi-TM-lactic-acid-citric-acid-and-potassium-bitartrate-the-First-and-Only-Non-Hormonal-Prescription-Gel-for-the-Prevention-of-Pregnancy",
        "note": "FDA Approval announced May 22, 2020.",
        "company_entity_id": 487,
        "company_ticker": "EVFM",
        "company_name": "Evofem Biosciences Inc.",
        "company_price": "0.0210",
        "company_change": 0,
        "company_percent_change": -4.55,
        "company_optionable": 0,
        "company_number_of_shares": 10730210,
        "price_change_sparkline": [
            [
                0.0268,
                1706677200
            ],
            [
                0.0291,
                1706763600
            ],
            [
                0.0297,
                1706850000
            ],
            [
                0.0256,
                1707109200
            ],
            [
                0.02886,
                1707195600
            ],
            [
                0.0314,
                1707282000
            ],
            [
                0.0306,
                1707368400
            ],
            [
                0.0304,
                1707454800
            ],
            [
                0.033,
                1707714000
            ],
            [
                0.0303,
                1707800400
            ],
            [
                0.034,
                1707886800
            ],
            [
                0.033,
                1707973200
            ],
            [
                0.033,
                1708059600
            ],
            [
                0.032,
                1708405200
            ],
            [
                0.027,
                1708491600
            ],
            [
                0.0268,
                1708578000
            ],
            [
                0.025,
                1708664400
            ],
            [
                0.0211,
                1708923600
            ],
            [
                0.01776,
                1709010000
            ],
            [
                0.0168,
                1709096400
            ],
            [
                0.016,
                1709182800
            ],
            [
                0.0167,
                1709269200
            ],
            [
                0.0152,
                1709528400
            ],
            [
                0.0159,
                1709614800
            ],
            [
                0.015,
                1709701200
            ],
            [
                0.027,
                1709787600
            ],
            [
                0.0199,
                1709874000
            ],
            [
                0.022,
                1710129600
            ],
            [
                0.021,
                1710216000
            ]
        ],
        "statuses": []
    }
]